Lowest Price Guaranteed
Pages
210
Last Updated
January 2026
View Count
18897
The generative AI in healthcare market, valued at USD 3.3 billion in 2025, is projected to reach USD 4.7 billion in 2026 and USD 39.8 billion by 2035, with a 26.7% CAGR during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
The new research study consists of industry trends, detailed market analysis, company competitiveness analysis, partnerships and collaborations, porter’s five forces analysis and market impact analysis, along with growth forecast for generative AI in healthcare market.
Generative AI is a part of artificial intelligence that leverages generative models to produce insights, videos, images and other forms of data. In the realm of healthcare, gen AI is a rapidly evolving technology that has shown promise to revolutionize patient care, research and treatment.
 |
 |
 |
It is worth highlighting that the healthcare industry is currently navigating a complex landscape marked by a multitude of challenges, including inefficiencies in clinical workflow, high treatment costs, workforce shortages, and burnout of healthcare providers. According to Medscape’s Physician Burnout and Depression Report, 49% of physicians felt burnt out in 2024 due to administrative tasks (62%) and excessive working hours (41%). In addition, traditional methods for drug discovery and development have led to prolonged timelines, with no focus on tailored treatment options. It has also been observed that, despite the extensive cost and time investment, approximately 90% of the drug candidates fail to reach advanced phases of clinical trials. This high failure rate has not only hindered innovation but has also intensified the financial pressure on healthcare systems, globally.
In order to overcome these challenges and enhance various healthcare processes, several pharmaceutical and life sciences companies have shown interest towards utilization of generative AI in the healthcare industry. Notably, gen AI holds the potential to streamline operations by automating administrative tasks (increasing operational efficiency), improving diagnostic accuracy through advanced imaging techniques (enhancing clinical outcomes), augmenting patient engagement by delivering personalized medicine, and accelerating drug discovery and development processes.
 |
 |
 |
Further, it is worth highlighting that implementing generative AI in pharma for administrative tasks can lead to substantial annual savings (of around $150 billion) across the healthcare sector. Furthermore, a study shows that it can reduce diagnostic errors by around 85% and reduce nursing overtime by 21%, translating into theoretical cost savings of approximately $469,000 over three years per hospital. Conversely, as healthcare organizations strive to harness the transformative potential of generative AI, it is crucial to develop robust frameworks that ensure ethical use of AI and mitigate the potential challenges related with the usage of ai tools, such as data privacy, algorithmic bias and transparency.
 |
 |
 |
Over the past few years, various pharmaceutical and healthcare companies have signed strategic partnerships with companies active in generative AI in healthcare domain to utilize gen AI for various applications in the healthcare industry. Moreover, generative AI companies are receiving significant funding and investments to develop and improve generative AI models that can be leveraged in different healthcare practices. Therefore, owing to the increased interest from investors and growing partnerships trend in this field, we anticipate the generative AI in healthcare market to witness healthy growth during the forecast period.
The market research report presents an in-depth analysis of the various generative AI in healthcare companies, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Current Market Size | $ 4.7 Billion | |
| Market Size 2035 | $ 39.8 Billion | |
| CAGR (Till 2035) | 26.7% | |
| Purpose |
|
|
| Type of Offering |
|
|
| Application Area |
|
|
| End-User |
|
|
| Key Geographical Regions |
|
|
| Market in North America |
|
|
| Market in Europe |
|
|
| Market in Asia-Pacific |
|
|
| Market in Middle East and North Africa |
|
|
| Market in Latin America |
|
|
| Key Generative AI in Healthcare Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 10% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period.
The generative AI in healthcare market analysis also features the likely distribution of the current and forecasted opportunity across various segments, such as purpose (clinical-based purpose and system-based purpose), type of offering (technology / platform and services), application area (drug discovery and development, diagnosis, treatment, administrative tasks and other application areas), end-user (pharmaceutical and life science companies, healthcare providers and other end-users), key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The market report features detailed transcripts of interviews held with the following individuals:
Notably, all the actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on purpose, this market report distributes the global generative AI in healthcare market into clinical-based and system-based purposes. Currently, the clinical-based purpose segment captures the maximum share (70%) in the overall market, followed by system-based purpose segment. It is worth noting that this trend is unlikely to change during the forecast period.
The global generative AI in healthcare market is categorized into platform / technology and service, based on type of offering. Currently, the market is driven by the platform / technology segment that captures more than 75% of the market share. Some notable examples of generative AI platforms in healthcare include BioNeMo (NVIDIA), Chemistry42 (Insilico Medicine) and Makya (Iktos). It is worth highlighting that the market for service segment is expected to grow at a relatively high CAGR (33%), till 2035. This rise in demand for generative AI services can be attributed to the growing adoption of generative AI technology, and integration and interoperability challenges associated with the gen AI solutions.
The global generative AI in healthcare market is divided across various sub-segments based on the type of application area, such as drug discovery and development, diagnosis, treatment, administrative tasks and other application areas. The treatment segment dominates the market in 2026, and this trend is unlikely to change in the future as well. This can be attributed to the increasing reliance on generative AI models to enhance treatment efficacy and streamline patient care processes. Additionally, implementing generative AI technology has the potential to reduce the administrative burden on healthcare professionals, allowing them to focus more on direct patient care, thereby driving the sustained growth of this segment.
The global market is segmented into different end-users, including pharmaceutical and life science companies, healthcare providers and other end-users. Currently, the healthcare providers segment captures the maximum (53%) share in the generative AI in healthcare market and this trend is unlikely to change during the forecast period, till 2035. This is attributed to the various benefits offered by gen AI solutions, such as enhanced patient care, improved operational efficiency, data driven insights and cost saving potential.
This segment highlights the distribution of market for generative AI in healthcare across various geographies, such as North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America. According to our projections, North America is likely to capture the majority (56%) of the current generative AI in healthcare market share, and this trend is unlikely to change in the future. The dominance of North America is attributed to the growing technological infrastructure and early adoption of advanced healthcare solutions, coupled with research and development investment, and high concentration of generative AI in healthcare providers in this region.
It is worth highlighting that the market in Asia-Pacific is expected to grow at a relatively higher CAGR (29%), during the forecast period. This can be attributed to the rapid digital transformation and developing tech ecosystem in countries like China, India, Japan and South Korea.
The “Generative AI in Healthcare Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, company competitiveness analysis, partnership and collaboration analysis and market size and future opportunities within the generative AI in healthcare industry, during the forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging industry. Key takeaways of the market report have been briefly discussed below.
Generative AI solutions have emerged as promising tool in the healthcare industry. These AI solutions / ai tools help healthcare stakeholders improve the accuracy and efficiency of diagnosis, accelerate drug discovery, optimize clinical trial outcomes, personalize treatment options and streamline administrative processes. In addition, leveraging generative AI technology in healthcare operations, reduces time and cost associated with different healthcare applications, such as diagnosis, patient treatment, drug discovery and reimbursement. It is worth highlighting that the ability of generative AI to automate and streamline labor-intensive tasks, improve clinical decision-making, and generate insights by identifying patterns and trends in complex datasets has gained significant traction from stakeholders in the healthcare space.
As a result of the benefits associated with the adoption of generative AI in healthcare practices, several generative AI companies have developed generative AI-powered platforms that optimize healthcare workflows. Additionally, generative AI algorithms can be trained to analyze large amounts of data in electronic health records to identify participants eligible for clinical trials. Additionally, the integration of gen AI in EHR has introduced conversational EHR, which assists users to collect relevant patient information by asking questions with the help of natural language processing technology. This has resulted in enhanced patient engagement and improved provider satisfaction.
Owing to these applications and recognition of the immense potential of generative AI by different end-users in the healthcare industry, the demand for generative AI in healthcare is likely to continue to grow and transform the landscape of drug development, treatment and diagnosis.
The generative AI in healthcare market landscape is highly fragmented, featuring the presence of both established companies as well as emerging generative AI start-ups. Currently, close to 60 players have the required expertise to offer various generative ai tools to streamline healthcare operations. Notably, at present, more than 85% of these generative AI providers are offering technology / platforms to streamline various processes in the healthcare industry.
Further, around 50% of the players are offering generative AI-based platforms and services for virtual nursing assistance applications. The increasing adoption of generative AI-based platforms and services for virtual nursing assistance in healthcare is driven by the need to alleviate administrative burden on healthcare workers. By automating routine tasks such as note-taking, appointment scheduling and patient inquiries, these generative AI systems significantly reduce the time clinicians spend on paperwork, allowing them to focus more on direct patient care. Akasa, a generative AI startup established in 2018 is using generative AI to streamline medical coding process in the hospitals and also supports claims management.
Recent developments in this field indicate that the gen AI companies in healthcare are upgrading their capabilities to accommodate the current and anticipated demand for these software and services. In fact, a US based start-up, Orchid Exchange, launched its HIPAA compliant AI powered EHR for mental health clinicians, helping reduce the time taken to write clinical notes from 20 minutes to a few seconds.
In recent years, several gen AI companies have signed partnerships related to generative AI in healthcare domain with other industry / non-industry players. It is worth highlighting that the partnership and collaborations in this industry have increased significantly with a CAGR of 150%, in the last five years. Further, the product / technology utilization and integration agreements emerged as the most common types of partnerships inked by stakeholders in the generative AI in healthcare sector.
Furthermore, owing to several advantages of gen AI, stakeholders are acquiring other industry players offering generative AI solutions for different healthcare applications in order to expand their capabilities and build a comprehensive product / service portfolio. In September 2024, Hackett Group acquired LeewayHertz, a recognized provider of advanced generative AI solutions to enhance its end-to-end generative AI solutions for its clients.
In addition, several big pharma companies (such as AstraZeneca, Bayer, Boehringer Ingelheim, Moderna and Pfizer) and number of non-industry players (such as Department of Health-Abu Dhabi, Duke Health, Los Alamos National Laboratory, Mass General Brigham and University of Wisconsin-Madison) have also taken partnership initiatives related to generative AI in healthcare use cases, indicating the promise and benefits that generative AI technology holds in healthcare industry. In September 2024, Insilico Medicine and Inimmune entered into a partnership agreement to leverage Chemistry42, Insilico’s proprietary generative artificial intelligence platform to expedite immunotherapies discovery and development. Likewise, in June 2024, Eli Lilly inked a partnership with OpenAI in order to utilize the latter’s generative AI technology for discovery of novel antimicrobials to treat drug-resistant pathogens.
The heightened interest in generative AI in healthcare market can be validated by the growing investments in generative AI startups engaged in providing gen ai tools for various healthcare applications, across the globe. It is worth noting that funding through venture capital plays a major role in this domain. According to a report by Silicon Valley Bank, one in four USD invested in the healthcare domain is received by companies utilizing AI. In October 2024, Suki, a healthcare AI startup has raised $70 million in Series D venture funding round to build generative AI-based assistants for hospitals. Similarly, in May 2024, Atropos Health has received a series B venture capital funding of $33 million to boost the adoption of generative AI in healthcare.
The global generative AI in healthcare market size is estimated to be worth $4.7 billion in 2026. Further, in terms of the end-users, the healthcare providers segment is likely to capture majority of the market. The increased interest of healthcare providers in adoption of generative AI technology can be attributed to its various advantages, such as time and cost saving potential, along with streamlining healthcare workflows. On the contrary, the market size for pharmaceutical and life science companies is anticipated to grow at a relatively higher CAGR of 29% during the forecast period.
The majority of the generative AI healthcare companies are headquartered in North America, followed by Europe. Notably, the global generative AI in healthcare market in 2035 is anticipated to be dominated by the players based in North America (56%) owing to the rapidly growing partnership activity and technological innovations in this region, resulting in the continuous enhancement of generative AI offerings for various applications by various stakeholders headquartered in this region. Further, 22% market share is anticipated to be captured by the players based in Europe. However, the market in Asia-Pacific is expected to grow at a relatively high CAGR (29%), till 2035.
Examples of the key generative ai healthcare companies (the complete list of players is available in the full report) include (in alphabetic order) Amazon Web Services, C3 AI, Exscientia, Google, Huma, IBM, Iktos, LeewayHertz, Medical IP, Microsoft, NVIDIA, OpenAI, Oracle, PhamaX and Syntegra. This market report also includes an easily searchable excel database of all the generative AI technology / platform and service providers for various healthcare applications, worldwide.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the generative AI in healthcare industry, across different geographies. Amongst other elements, the market report includes:
Several recent developments have taken place in the field of gen AI in healthcare, some of which have been outlined below. These developments substantiate the overall generative AI in healthcare market trends that we have outlined in our analysis.